Martin N.
- Country
- Germany
- Department
- Nephrology and Transplantation
Research Overview
- Efficacy and Safety Evaluation of Vemircopan in Adults with Proliferative Lupus Nephritis or Immunoglobulin A Nephropathy: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study
- Efficacy and Safety Evaluation of Ravulizumab in Adults with Proliferative Lupus Nephritis or Immunoglobulin A Nephropathy: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study
- Long-Term Safety and Efficacy Evaluation of Atacicept in Patients with IgA Nephropathy Following Completion of Parent Study Treatment Period
Data & Insights
Has run more than one trial at 45 of 122 partner sites.
Specializations
Kidney Disease Management
This investigator specializes in treating various forms of glomerular diseases, with particular emphasis on IgA Nephropathy (IgAN) and its progressive manifestations.
- Proteinuria reduction strategies
- Long-term disease management
- Glomerular function preservation
Their work encompasses innovative therapeutic approaches for chronic kidney conditions.
Autoimmune Nephrology
The investigator focuses on Lupus Nephritis (LN) and related autoimmune kidney disorders, including rapidly progressive glomerulonephritis.
- Immunological intervention strategies
- Novel therapeutic compounds
- Disease progression monitoring
Their expertise extends to advanced treatment protocols for autoimmune-mediated kidney diseases.
Chronic Disease Complex
The investigator addresses chronic kidney disease (CKD) with concurrent conditions, particularly focusing on the relationship between kidney function and hypertension.
- Cardiovascular outcomes in CKD
- Combined therapy approaches
- Renal function preservation
Their research encompasses comprehensive treatment strategies for complex kidney disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.